Publisher's Synopsis
This monograph looks at moxonidine, a new, centrally-acting therapy for hypertension. In discussing the receptor-binding characteristics and experimental pharmacology of moxonidine and clinical experience with the drug to date, this is an up-to-date profile of this compound.;Moxonidine has the potential to become a most useful addition to the armamentarium of antihypertensive drugs. Of equal importance is the recognition that drugs which act as imidazoline receptors represent a novel central mechanism for the reduction of elevated blood pressure.
